Technology Webinar

Translating Genetic Biomarkers to the Clinic: The Promise and Pitfalls of Developing Robust, Reliable Signatures

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Translating Genetic Biomarkers to the Clinic:  The Promise and Pitfalls of Developing Robust, Reliable Signatures

Recorded 03 October 2012

Speakers

Downloads

As our understanding of the human genome expands, so does the desire to translate this knowledge into effective clinical tools. With a growing number of complex genomic tests for biomarker signatures becoming commercially available, the promise of personalized medicine is fast becoming a reality. Although researchers and clinicians are continuously striving to enable quicker and more individualized treatment decisions, the development of these tests is a long road, with discovery and validation of genomic biomarker signatures just the start. Our expert panel will discuss the practicalities of developing a test from signature discovery and validation all the way to clinic.

During the webinar, topics discussed will include:
• Considerations for developing a robust, clinically relevant test
• Practicalities of clinical trials, such as sample size and availability considerations
• Navigating the regulatory approval process.

You’ll also have the opportunity to ask questions of the panelists during the live Q&A session.

 

For more information on products/technologies related to this webinar, go to:  www.affymetrix.com/pba_partners

Speaker bios

Timothy J. Yeatman, M.D., F.A.C.S.

Moffitt Cancer Center
Tampa, FL

Dr. Yeatman received his undergraduate degree at Duke University and his medical degree from Emory University. He completed his surgical internship and residency at the University of Florida, and then a Surgical Oncology Fellowship at M.D. Anderson Cancer Center. Dr. Yeatman is currently professor of oncologic sciences and section head of hepatobiliary surgery at Moffitt Cancer Center. He has previously served as president and founding chief scientific officer for M2Gen, a wholly owned subsidiary of Moffitt Cancer Center. He now serves as chief scientific officer to the Center for Advancement of Science in Space (CASIS), a non-profit entity established by Congress to oversee all scientific activities on the International Space Station and will shortly become the director of the Gibbs Cancer Center in Spartanburg, South Carolina. 

Dr. Yeatman has focused his research on the management of gastrointestinal malignancies with a special research emphasis on using genome scale microarrays to identify the molecular signatures of cancer that provide diagnosis, prognosis, and response to therapy. Dr. Yeatman was the principal investigator for “Total Cancer Care”, a large initiative in personalized medicine that tied molecular data to longitudinal clinical data to support ongoing preclinical and clinical research efforts to promote the discipline of personalized medicine. Dr. Yeatman has published more than 200 articles in the top peer-reviewed journals in his field and has received numerous honors and awards including the Center Director's Award for Outstanding Research at Moffitt Cancer Center three times (1995, 1997, and 1998).
 

Henk Viëtor, M.D., Ph.D.

Skyline Diagnostics
Rotterdam, The Netherlands

Dr. Viëtor graduated from medical school at the University of Amsterdam. After completing his training as an M.D., he specialized in (clinical) immunology and transfusion medicine at the University Medical Centre in Leiden, The Netherlands. He completed his thesis on the development of the fetal immune system and then specialized in clinical genetics at the University Medical Centre, St. Radboud in Nijmegen. His results were published in numerous leading scientific journals. In addition to these achievements, Dr. Viëtor was editor for the Proceedings of the Society for Experimental Biology and Medicine. He is also credited as an inventor on several patents. He became involved in the life sciences industry in 2001 as CEO of Multigen Nederland BV (an advisory and investment holding) where he worked until 2003. Since then, he has been an active entrepreneur in the industry and is co-founder of more than 15 biotechnology spin-off companies including Skyline Diagnostics, Dynomics, Immunaffect, Recharge, Drug Discover Factory, DC4U, and Mylife. He is on the board of the Center for Translational Medicine, Skyline Diagnostics, and Biofarmind (a life sciences association organization in the Netherlands).

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here